https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 The role of the blood-brain barrier during neurological disease and infection https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53016 Wed 28 Feb 2024 16:09:05 AEDT ]]> Blood-brain barrier disruption in atrial fibrillation: a potential contributor to the increased risk of dementia and worsening of stroke outcomes? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45212 Wed 26 Oct 2022 15:56:18 AEDT ]]> Brain microvascular endothelial-astrocyte cell responses following Japanese encephalitis virus infection in an in vitro human blood-brain barrier model https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33005 in vivo situation. The effects of JEV on the BBB permeability and release of inflammatory mediators from both apical and basolateral sides, representing the blood and the brain side respectively were investigated. JEV infected HBECs with limited active virus production, before crossing the BBB and infecting astrocytes. Control of JEV production by HBECs was associated with a significant increase in permeability, and with elevation of many host mediators, including cytokines, chemokines, cellular adhesion molecules, and matrix metalloproteases. When compared to the controls, significantly higher amounts of mediators were released from the apical side as opposed to the basolateral side. The increased release of mediators over time also correlated with increased BBB permeability. Treatment with dexamethasone led to a significant reduction in the release of interleukin 6 (IL6), C-C motif chemokine ligand 5 (CCL5) and C-X-C motif chemokine ligand 10 (CXCL10) from the apical side with a reduction in BBB disruption and no change in JEV production. The results are consistent with the hypothesis that JEV infection of the BBB triggers the production of a range of host mediators from both endothelial cells and astrocytes, which control JEV production but disrupt BBB integrity thus allowing virus entry into the brain. Dexamethasone treatment controlled the host response and limited BBB disruption in the model without increasing JEV production, supporting a re-investigation of its use therapeutically.]]> Wed 10 Nov 2021 15:13:54 AEDT ]]> Blood-brain barrier disturbances in diabetes-associated dementia: therapeutic potential for cannabinoids https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35136 Wed 10 Nov 2021 15:04:22 AEDT ]]> Investigating the processes of age-related inflammation in the central nervous system https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40064 Wed 06 Mar 2024 15:05:45 AEDT ]]> Current status and advances to improving drug delivery in diffuse intrinsic pontine glioma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55532 Wed 05 Jun 2024 09:23:06 AEST ]]> DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48767 Wed 05 Apr 2023 13:55:36 AEST ]]> Leakage beyond the primary lesion: A temporal analysis of cerebrovascular dysregulation at sites of hippocampal secondary neurodegeneration following cortical photothrombotic stroke https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54067 Tue 30 Jan 2024 13:56:39 AEDT ]]> Targeting innate immunity for neurodegenerative disorders of the central nervous system https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50026 Tue 27 Jun 2023 16:47:33 AEST ]]> Reperfusion facilitates reversible disruption of the human blood-brain barrier following acute ischaemic stroke https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36740 hypo-i), non-hypoperfused region of ischaemic hemisphere (rPSnonhypo-i) and their contralateral mirror regions (rPShypo-c and rPSnonhypo-c). The changes of rPS were analysed using analysis of variance (ANOVA) with repeated measures. Logistic regression was used to identify independent predictors of unfavourable outcome. Results: Fifty-six patients were included in the analysis, median age was 76 (IQR 62-81) years and 28 (50%) were female. From baseline to 24 h after treatment, rPShypo-i, rPSnonhypo-i and rPShypo-c all decreased significantly. The decreases in rPShypo-i and rPShypo-c were larger in the reperfusion group than non-reperfusion group. The rPShypo-i at follow-up was a predictor for unfavourable outcome (OR 1.131; 95% CI 1.018-1.256; P = 0.022). Conclusion: Early disruption of BBB in AIS is reversible, particularly when greater reperfusion is achieved. Elevated BBBP at 24 h after treatment, not the pretreatment BBBP, predicts unfavourable outcome. Key points: Early disruption of blood-brain barrier (BBB) in stroke is reversible after treatment; The reversibility of BBB permeability is associated with reperfusion; Unfavourable outcome is associated with BBB permeability at 24 h after treatment; Contralateral non-ischaemic hemisphere is not 'normal' during an acute stroke.]]> Thu 02 Jul 2020 16:31:45 AEST ]]> The rise of pericytes in neurovascular research https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42682 Thu 01 Sep 2022 08:45:21 AEST ]]> Vascular senescence and leak are features of the early breakdown of the blood–brain barrier in Alzheimer’s disease models https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53851 Fri 19 Jan 2024 10:25:09 AEDT ]]>